Cargando…

Corrigendum: The Reversal Effect of Sigma-1 Receptor (S1R) Agonist, SA4503, on Atrial Fibrillation After Depression and Its Underlying Mechanism

Detalles Bibliográficos
Autores principales:	Liu, Xin, Qu, Chuan, Shi, Shaobo, Ye, Tianxin, Wang, Linglin, Liu, Steven, Zhang, Cui, Liang, Jinjun, Hu, Dan, Yang, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017813/ https://www.ncbi.nlm.nih.gov/pubmed/35450160 http://dx.doi.org/10.3389/fphys.2022.846676

Ejemplares similares

The Reversal Effect of Sigma-1 Receptor (S1R) Agonist, SA4503, on Atrial Fibrillation After Depression and Its Underlying Mechanism
por: Liu, Xin, et al.
Publicado: (2019)

Sigma-1 Agonist Binding in the Aging Rat Brain: a MicroPET Study with [(11)C]SA4503
por: Ramakrishnan, Nisha K., et al.
Publicado: (2015)

Comparison of Sigma 1 Receptor Ligands SA4503 and PRE084 to (+)-Pentazocine in the rd10 Mouse Model of RP
por: Wang, Jing, et al.
Publicado: (2020)

Steroid hormones affect binding of the sigma ligand (11)C-SA4503 in tumour cells and tumour-bearing rats
por: Rybczynska, Anna A., et al.
Publicado: (2009)

SA4503, A Potent Sigma-1 Receptor Ligand, Ameliorates Synaptic Abnormalities and Cognitive Dysfunction in a Mouse Model of ATR-X Syndrome
por: Yamaguchi, Kouya, et al.
Publicado: (2018)

Retrospective cohort study of new-onset atrial fibrillation in acute pulmonary embolism on prognosis
por: Liu, Dishiwen, et al.
Publicado: (2021)

Corrigendum: Pinocembrin Decreases Ventricular Fibrillation Susceptibility in a Rat Model of Depression
por: Ye, Tianxin, et al.
Publicado: (2021)

Chronic Sigma 1 receptor activation alleviates right ventricular dysfunction secondary to pulmonary arterial hypertension
por: Sun, Yazhou, et al.
Publicado: (2022)

4503 Adaptation of Motor Action in Children with Hemiplegic Cerebral Palsy
por: Dimitropoulou, Katherine, et al.
Publicado: (2020)

Left Atrial Thrombus in Patients With Non-valvular Atrial Fibrillation: A Cross-Sectional Study in China
por: Shi, Shaobo, et al.
Publicado: (2022)

Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer
por: Bothwell, Katelyn D., et al.
Publicado: (2016)

Pinocembrin Decreases Atrial Fibrillation Susceptibility in a Rodent Model of Depression
por: Ran, Qian, et al.
Publicado: (2022)

Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes
por: Basheer, Loai, et al.
Publicado: (2015)

miR-216a exacerbates TGF-β-induced myofibroblast transdifferentiation via PTEN/AKT signaling
por: Qu, Chuan, et al.
Publicado: (2019)

Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Corrigendum: Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes
por: Boriani, Giuseppe, et al.
Publicado: (2017)

Pinocembrin Decreases Ventricular Fibrillation Susceptibility in a Rat Model of Depression
por: Ye, Tianxin, et al.
Publicado: (2020)

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
por: Fifis, Theodora, et al.
Publicado: (2013)

GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?
por: Stoll, Lisa, et al.
Publicado: (2023)

Sigma-1 Receptor Agonists Directly Inhibit Na(V)1.2/1.4 Channels
por: Gao, Xiao-Fei, et al.
Publicado: (2012)

Reversible atrial fibrillation following Crotalinae envenomation
por: Quan, Dan, et al.
Publicado: (2017)

Corrigendum to: Rotor mechanism and its mapping in atrial fibrillation
Publicado: (2023)

A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
por: Albayrak, Yakup, et al.
Publicado: (2019)

Sigma-1 Receptor Agonist Fluvoxamine Ameliorates Fibrotic Response of Trabecular Meshwork Cells
por: Hodrea, Judit, et al.
Publicado: (2023)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Pinocembrin ameliorates arrhythmias in rats with chronic ischaemic heart failure
por: Guo, Yan, et al.
Publicado: (2021)

Reversible atrial fibrillation secondary to a mega-oesophagus
por: Upile, Tahwinder, et al.
Publicado: (2006)

Corrigendum: Real-Time Rotational Activity Detection in Atrial Fibrillation
por: Ríos-Muñoz, Gonzalo R., et al.
Publicado: (2018)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists
por: Li, Jing, et al.
Publicado: (2023)

HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
por: Lanters, Eva A. H., et al.
Publicado: (2015)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

The synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system
por: Somogyi, Aleksandra, et al.
Publicado: (2023)

Inhibitory Effects of Sigma-2 Receptor Agonists on T Lymphocyte Activation
por: Iñiguez, Miguel A., et al.
Publicado: (2013)

Saint John's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of Willis-Ekbom's disease
por: Pereira, José Carlos, et al.
Publicado: (2013)

Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
por: Nguyen, Linh, et al.
Publicado: (2016)

Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management
por: Shamoun, Fadi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_djf21db3e5jhg73nioee5s8t22